{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:23:28Z","timestamp":1774574608880,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109367","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:58:44Z","timestamp":1765814324000},"page":"109367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of a dual-target CRBN-mediated degrader for IKZF1\/3 and GSPT1 proteins"],"prefix":"10.1016","volume":"169","author":[{"given":"Chunchao","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangliang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109367_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.immunol.15.1.155","article-title":"The role of the IKAROS gene in lymphocyte development and homeostasis","volume":"15","author":"Georgopoulos","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0010","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.immuni.2024.07.010","article-title":"Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity","volume":"57","author":"Ichiyama","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2025.109367_bb0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.apsb.2016.06.002","article-title":"The Ikaros family of zinc-finger proteins","volume":"6","author":"Fan","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109367_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis Int. J. Program. Cell Death"},{"key":"10.1016\/j.bioorg.2025.109367_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.immuni.2007.03.003","article-title":"Aiolos: an ungrateful member of the Ikaros family","volume":"26","author":"Kioussis","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2025.109367_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1440-1711.2003.01159.x","article-title":"Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies","volume":"81","author":"Rebollo","year":"2003","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/biomedicines12010089","article-title":"IKZF1 alterations and therapeutic targeting in B-cell acute lymphoblastic leukemia","volume":"12","author":"Paolino","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.109367_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000813","article-title":"IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?","volume":"135","author":"Stanulla","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.109367_bb0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/ijms22031103","article-title":"Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them","volume":"22","author":"Cippitelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109367_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug Lenalidomide promotes the Cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109367_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109367_bb0060","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0070","doi-asserted-by":"crossref","first-page":"11575","DOI":"10.1182\/blood-2022-166541","article-title":"CFT7455, a novel IKZF1\/3 degrader, demonstrates potent anti-tumor activity in models of non-Hodgkin's lymphoma as a single agent or in combination with clinically approved agents","volume":"140","author":"Perino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.109367_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel Cereblon modulator Avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109367_bb0080","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1128\/MCB.25.14.5801-5811.2005","article-title":"Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation","volume":"25","author":"Chauvin","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0085","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1093\/nar\/gkw635","article-title":"PABP enhances release factor recruitment and stop codon recognition during translation termination","volume":"44","author":"Ivanov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.109367_bb0090","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/med.22024","article-title":"Development and therapeutic potential of GSPT1 molecular glue degraders: a medicinal chemistry perspective","volume":"44","author":"Chang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109367_bb0095","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a Cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.109367_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117381","article-title":"Discovery of highly potent dual GSPT1\/BRD4 degraders with anti-AML activity","volume":"288","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109367_bb0115","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/acsmedchemlett.2c00223","article-title":"SJPYT-195: a designed nuclear receptor degrader that functions as a molecular glue degrader of GSPT1","volume":"13","author":"Huber","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109367_bb0120","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a Bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0125","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","article-title":"Identification of potent, selective, and orally bioavailable small-molecule GSPT1\/2 degraders from a focused library of Cereblon modulators","volume":"64","author":"Nishiguchi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0130","article-title":"Design and discovery of preclinical candidate LYG-409 as a highly potent and selective GSPT1 molecular glue degraders","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2019-123966","article-title":"Clinical activity of CC-90009, a Cereblon E3 ligase modulator and first-in-class GSPT1 degrader, as a single agent in patients with relapsed or refractory acute myeloid leukemia (R\/R AML): first results from a phase I dose-finding study","volume":"134","author":"Uy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.109367_bb0140","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1538-7445.AM2020-2048","article-title":"Abstract 2048: discovery of induction and release of IL-1b are unique and on-target effects of GSPT1 degradation that provide potential mitigation strategies to hypotension in the CC-90009-AML-001 phase 1 trial","volume":"80","author":"Yao","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109367_bb0145","series-title":"BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1\/3, for treatment of acute myeloid leukemia (AML) and solid tumors","author":"Chourasia","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109367_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nchembio.1309","article-title":"Small-molecule modulation of Wnt signaling via modulating the Axin-LRP5\/6 interaction","volume":"9","author":"Wang","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional Phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109367_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105505","article-title":"A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer","volume":"119","author":"Lier","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0170","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1021\/acs.jmedchem.4c02205","article-title":"Discovery of a potent and selective GSPT1 molecular glue degrader for the treatment of castration-resistant prostate Cancer","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2018.11.008","article-title":"Activating Wnt\/\u03b2-catenin signaling pathway for disease therapy: challenges and opportunities","volume":"196","author":"Huang","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"2316","key":"10.1016\/j.bioorg.2025.109367_bb0180","first-page":"e1","article-title":"Downregulation of Wnt\/\u03b2-catenin signaling causes degeneration of hippocampal neurons in vivo","volume":"32","author":"Kim","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bioorg.2025.109367_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Anastas","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109367_bb0200","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1021\/acs.jmedchem.5b00223","article-title":"Discovery of selective small-molecule inhibitors for the \u03b2-catenin\/T-cell factor protein\u2013protein interaction through the optimization of the acyl hydrazone moiety","volume":"58","author":"Catrow","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0205","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells12081110","article-title":"A new wave of targeting \u2018Undruggable\u2019 Wnt signaling for Cancer therapy: challenges and opportunities","volume":"12","author":"Park","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109367_bb0210","first-page":"186","article-title":"New insights into the regulation of Axin function in canonical Wnt signaling pathway, protein","volume":"5","author":"Song","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109367_bb0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopha.2018.11.082","article-title":"Therapeutic potential of targeting the Wnt\/\u03b2-catenin signaling pathway in colorectal cancer","volume":"110","author":"Cheng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109367_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117395","article-title":"Shikonin, a natural naphthoquinone phytochemical, exerts anti-leukemia effects in human CBF-AML cell lines and zebrafish xenograft models","volume":"179","author":"Yen","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109367_bb0225","article-title":"Targeted protein degradation induced by HEMTACs based on HSP90","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113307","article-title":"Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer","volume":"216","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0235","series-title":"MDAnalysis: A Python Package for the Rapid Analysis of Molecular Dynamics Simulations","first-page":"98","author":"Gowers","year":"2016"},{"key":"10.1016\/j.bioorg.2025.109367_bb0240","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: a toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Michaud-Agrawal","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.109367_bb0245","first-page":"72","article-title":"ProLIF: a library to encode molecular interactions as fingerprints","volume":"13","author":"Bouysset","year":"2021","journal-title":"J. Chemother."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T13:44:48Z","timestamp":1768657488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"alternative-id":["S0045206825012477"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109367","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a dual-target CRBN-mediated degrader for IKZF1\/3 and GSPT1 proteins","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109367"}}